Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $101.31 USD
Change Today +0.91 / 0.91%
Volume 1.1M
As of 8:04 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NVS) Key Developments

Novartis Accelerates Cancer Immunotherapy Efforts with Aduro Biotech Alliance and Launch of New Immuno-Oncology Research Group

Novartis announced that it is stepping up its efforts to harness the body's immune system to combat cancer. The company has entered into a major multiyear alliance with Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway and launched a new immuno-oncology research group led by renowned cancer vaccine expert Glenn Dranoff, MD. The addition of STING agonists adds firepower to Novartis' diverse portfolio of immunotherapies that includes chimeric antigen receptor T-cell (CART) technology and novel checkpoint inhibitors. Currently the CART program, CTL019, is in phase 2 clinical trials and checkpoint inhibitors targeting PD1, LAG3, and TIM3 are expected to enter the clinic in mid-2015. Under the terms of the agreement with Aduro, Novartis will make an upfront payment of $200 million to Aduro and will make an initial equity investment in the company for $25 million, with a commitment for another $25 million equity investment at a future date. Aduro will lead commercialization activities and book sales in the US, with Novartis leading commercialization and recognizing sales in the rest of the world. The companies will share in profits in the US, Japan and major European countries. Novartis will pay Aduro a royalty for sales in the rest of the world.

Novartis Announces Encouraging Two-Year Data from Psoriasis Study

Novartis has announced new two-year data from the extension study of the pivotal Phase III FIXTURE and ERASURE trials demonstrating sustained efficacy with Cosentyx with an acceptable safety profile for the treatment of psoriasis patients. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients. In this extension of the FIXTURE and ERASURE studies, 995 patients who achieved Psoriasis Area Severity Index (PASI) 75 response after a year of therapy (Week 52) received either Cosentyx 300 mg, Cosentyx 150 mg or placebo for an additional year (Week 104). After two full years of therapy, 7 out of 10 (70.6%) patients treated with Cosentyx 300 mg had clear to almost clear skin (PASI 90); 4 out of 10 (43.9%) had clear skin (PASI 100) and almost 9 out of 10 (88.2%) patients maintained their PASI 75 response at Week 104. For patients treated with Cosentyx 150 mg, 44.6% had clear or almost clear skin (PASI 90); 23.5% had clear skin (PASI 100) and 75.5% maintained their PASI 75 response at Week 104. PASI assesses treatment efficacy by measuring the reduction in redness, scaling and thickness of psoriatic plaques and the extent of involvement in each region of the body.

Sandoz Ltd. Wins GBP 220.9 Million Multiple Awardees Contract for Supplying Proprietary Pharmaceuticals

Sandoz Ltd. won a GBP 220.9 million (excluding VAT) multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of proprietary pharmaceuticals (Contract Award Notice No.: 2015/S 057-099494).

Novartis AG Presents Cosentyx(TM) Two Year Efficacy And Safety Data

Novartis announced new two-year results demonstrating sustained efficacy with Cosentyx(TM) (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. Results were presented for the first time in a late-breaking session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients. In this extension of the FIXTURE and ERASURE studies, 995 patients who achieved Psoriasis Area Severity Index (PASI) 75 response after a year of therapy (Week 52) received either Cosentyx 300 mg, Cosentyx 150 mg or placebo for an additional year (Week 104). After two full years of therapy, 7 out of 10 (70.6%) patients treated with Cosentyx 300 mg had clear to almost clear skin (PASI 90); 4 out of 10 (43.9%) had clear skin (PASI 100) and almost 9 out of 10 (88.2%) patients maintained their PASI 75 response at Week 104. For patients treated with Cosentyx 150 mg, 44.6% had clear or almost clear skin (PASI 90); 23.5% had clear skin (PASI 100) and 75.5% maintained their PASI 75 response at Week 104. PASI assesses treatment efficacy by measuring the reduction in redness, scaling and thickness of psoriatic plaques and the extent of involvement in each region of the body. In the study, 94.8% of patients who initially received placebo (at the start of the extension) and were switched to receive Cosentyx 300 mg after relapse, were able to achieve PASI 75 and 70.3% achieved PASI 90 within 12 weeks of re-starting Cosentyx treatment. Cosentyx demonstrated an acceptable safety profile. The most common adverse events (AEs) for the 300 mg and 150 mg treatment arms were nasopharyngitis (24.1% and 17.0%, respectively), upper respiratory tract infection (5.3% and 5.0%), hypertension (4.3% and 5.2%), headache (5.6% and 2.9%) and arthralgia (4.0% and 4.2%). Infections and infestations were reported in 53.1% of patients receiving Cosentyx 300 mg and 41.6% of patients receiving 150 mg. There were 64 (6.0%) serious AEs (SAEs) in any Cosentyx dose and no deaths reported during the study. Patients who had been receiving Cosentyx 300 mg or 150 mg during the maintenance period of the core studies, and who exhibited a PASI 75 response at Week 52 of the core studies, were randomized to continue the same Cosentyx dose or receive placebo. Patients who exhibited partial response (PASI 50 to (PASI 75 response) from baseline at Week 52 of the core studies were also eligible to enter A2302E, but did not enter the randomized withdrawal extension study. Partial responders instead continued the same treatment dose (Cosentyx 300 mg or 150 mg) that they received at the time of completing the maintenance period (Week 52) in the core studies. Non-responders (patients who did not achieve at least a PASI 50 response at Week 52 of the core study) were not eligible to enter any part of this extension study. During the extension study, patients randomized to placebo and who experienced relapse (defined as loss of)50% of the maximum PASI gain compared to baseline of the core study) at any study visit received Cosentyx 300 mg or 150 mg, respectively, once weekly for 4 weeks, followed by Cosentyx dosing every 4 weeks thereafter.

David Sanford, Chairman of Sanford Heisler Kimpel LLP, Files Title VII and Equal Pay Act Against Novartis and its Alcon Division

David Sanford, Chairman of Sanford Heisler Kimpel LLP, filed a Title VII and Equal Pay Act case against Novartis and its Alcon division. Sanford Heisler Kimpel filed the suit in the U.S. District Court for the Southern District of New York. The lawsuit seeks $110 million, company-wide changes to redress gender discrimination, and individual relief. The plaintiffs in the Complaint are Fort Worth resident Elyse Dickerson, on behalf of herself, and Pennsylvania resident Dr. Susan Orr, on behalf of herself and similarly situated women at in the Alcon division who also experienced gender discrimination. The two plaintiffs were both Global Directors in Novartis's Alcon division. Novartis and its Alcon division discriminated against them by paying them less than males in similar positions, giving them less favorable work assignments and career-enhancing opportunities, and denying them promotions in favor of men in similar positions. Both women characterize Alcon as having a boy's club environment and mentality hostile to women and their careers. In violation of federal law, Novartis and Alcon retaliated against Ms. Dickerson for her complaints of gender discrimination, downgrading her performance ratings and ultimately terminating her employment in January 2015, while she was on federally protected medical leave. The illegal termination took place just over two weeks before some $750,000 of Ms. Dickerson's Novartis stock grants were scheduled to vest. Dr. Orr sues on her own behalf and on behalf of similarly situated women who held director-level positions in Novartis's Alcon division. Dr. Orr's collective action claim cites Novartis' and Alcon's violations of the Fair Labor Standards Act of 1938, as amended by the Equal Pay Act of 1963, for denial of equal pay for equal work. Dr. Orr also brings an individual claim that faults Novartis and Alcon for pay discrimination in violation of Title VII.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $101.31 USD +0.91

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $100.69 USD -0.31
Johnson & Johnson $101.55 USD +1.21
Merck & Co Inc $58.34 USD +0.59
Pfizer Inc $35.00 USD +0.47
Roche Holding AG SFr.269.50 CHF +4.50
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 23.2x
Price/Sales 4.5x
Price/Book 3.4x
Price/Cash Flow 26.5x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.